<DOC>
	<DOCNO>NCT02117219</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 study ass safety antitumor activity MEDI4736 Monotherapy Combination Tremelimumab without Azacitidine Subjects myelodysplastic syndrome treatment hypomethylating agent</brief_summary>
	<brief_title>Phase 1 Study Evaluate MEDI4736 Subjects With Myelodysplastic Syndrome</brief_title>
	<detailed_description>A dose-escalation dose-expansion study MEDI4736 ( monoclonal antibody target program cell death-1 ligand 1 [ PD-L1 ] ) evaluate safety , tolerability , PK , IM , antitumor activity MEDI4736 monotherapy combination Tremelimumab without Azacitidine adult patient myelodysplastic syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Adult male female subject pathologically confirm MDS fail respond , relapse initial response , unable tolerate hypomethylating agent , ECOG performance status 0 2 , adequate organ marrow function . Concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment , prior MAb CTLA4 , PD1 , PDL1 , alllogenic haploidentical transplant , current immunosuppressive medication autoimmune inflammatory disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>